Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Patient-derived Tumor Organoids with P53 Mutations, and Not Wild-Type P53, Are Sensitive to Synergistic Combination PARP Inhibitor Treatment

Florencia P. Madorsky Rowdo,Gu Xiao,Galina F. Khramtsova,John Nguyen,Rachel Martini,Brian Stonaker,Richard Boateng,Joseph K. Oppong,Ernest K. Adjei,Baffour Awuah,Ishmael Kyei,Frances S. Aitpillah,Michael O. Adinku,Kwasi Ankomah,Ernest B. Osei-Bonsu,Kofi K. Gyan,Nasser K. Altorki,Esther Cheng,Paula S. Ginter,Syed Hoda,Lisa Newman,Olivier Elemento, Olufunmilayo I. Olopade,Melissa B. Davis,M. Laura Martin,Jill Bargonetti

Cancer Letters（2024）

Cited 2|Views44
Key words
Patient-derived tumor organoids,PARP inhibitor,Mutant p53,Synergistic cytotoxicity,DNA double-strand breaks
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined